Fostamatinib – IgAN

Fostamatinib


Oral SYK Inhibitor for IgA Nephropathy:


  • A major function of the kidneys is to eliminate and dispose of waste products by filtering the blood and producing urine.
  • IgA Nephropathy (IgAN) is a chronic autoimmune disease associated with inflammation in the kidneys that diminishes their ability to filter blood.
  • IgAN is the most common primary glomerular disease. There are an estimated 82,500 - 165,000 cases in the US, with a higher prevalence in Asia.
  • Outside of angiotensin blockade (primarily for blood-pressure control), there are no disease-targeted therapies for IgAN.
  • Pre-clinical data show that fostamatinib, Rigel's oral SYK inhibitor, may decrease SYK activation in the kidney, resulting in the reversal of the inflammation in the glomeruli and improvement in kidney function.
  • Rigel announced results of the first cohort (100mg BID, n=26; placebo n=12) of a Phase 2 study of fostamatinib in IgAN in January 2017. Rigel expects that the second cohort, evaluating a higher dose of fostamatinib (150mg BID), will finish enrollment in 2017 with full results in 2018.


Clinical Trials:

Phase 2 - IgA Nephropathy

MOA Animation: